Interferon-α for alarming hemangiomas in infants: Experience of a single institution

Yu Hua Chao, Der Cherng Liang, Shu Huey Chen, Lin Yen Wang, Ting Chi Yeh, Hsi Che Liu

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Hemangioma is the most common tumor in infancy. 'Alarming hemangiomas' refer to the lesions that potentially impair vital structures or cause life-endangering complications, and which warrant vigorous treatment. Interferon-α has been used for alarming hemangiomas at Mackay Memorial Hospital, Taipei, Taiwan, since 1994. Methods: The records of 21 consecutive infants treated between January 1994 and December 2005 were retrospectively reviewed. The initial dose of interferon-α was 50 000 IU/kg per day, which was increased to 100 000 IU/kg per day in the second week of therapy if tolerated. It was tapered depending on response, with total treatment lasting no longer than 12 months. Treatment response was evaluated depending on the size of the lesion and resolution of complications. Results: The duration of therapy ranged from 6 to 12 months. Six patients (29%) had a reduction in mass of ≥25% after 1 month of therapy. Twenty patients (95%) had achieved a decrease in size of 50% by 12 months, and 15 (71%) had total involution of lesions by a median age of 13.5 months (range 7-50 months). Only mild and transient adverse effects were encountered. No neurologic complications occurred. Conclusions: Interferon-α appears to be an effective and well-tolerated treatment for alarming hemangiomas in infancy.

Original languageEnglish
Pages (from-to)469-473
Number of pages5
JournalPediatrics International
Volume51
Issue number4
DOIs
Publication statusPublished - Aug 2009
Externally publishedYes

Fingerprint

Hemangioma
Interferons
Therapeutics
Taiwan
Nervous System
Neoplasms

Keywords

  • Hemangioendothelioma
  • Hemangioma
  • Infant
  • Interferon-α
  • Kasabach-Merritt syndrome

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Interferon-α for alarming hemangiomas in infants : Experience of a single institution. / Chao, Yu Hua; Liang, Der Cherng; Chen, Shu Huey; Wang, Lin Yen; Yeh, Ting Chi; Liu, Hsi Che.

In: Pediatrics International, Vol. 51, No. 4, 08.2009, p. 469-473.

Research output: Contribution to journalArticle

Chao, Yu Hua ; Liang, Der Cherng ; Chen, Shu Huey ; Wang, Lin Yen ; Yeh, Ting Chi ; Liu, Hsi Che. / Interferon-α for alarming hemangiomas in infants : Experience of a single institution. In: Pediatrics International. 2009 ; Vol. 51, No. 4. pp. 469-473.
@article{6bdf4114de8049d4a1b9a8670fcda686,
title = "Interferon-α for alarming hemangiomas in infants: Experience of a single institution",
abstract = "Background: Hemangioma is the most common tumor in infancy. 'Alarming hemangiomas' refer to the lesions that potentially impair vital structures or cause life-endangering complications, and which warrant vigorous treatment. Interferon-α has been used for alarming hemangiomas at Mackay Memorial Hospital, Taipei, Taiwan, since 1994. Methods: The records of 21 consecutive infants treated between January 1994 and December 2005 were retrospectively reviewed. The initial dose of interferon-α was 50 000 IU/kg per day, which was increased to 100 000 IU/kg per day in the second week of therapy if tolerated. It was tapered depending on response, with total treatment lasting no longer than 12 months. Treatment response was evaluated depending on the size of the lesion and resolution of complications. Results: The duration of therapy ranged from 6 to 12 months. Six patients (29{\%}) had a reduction in mass of ≥25{\%} after 1 month of therapy. Twenty patients (95{\%}) had achieved a decrease in size of 50{\%} by 12 months, and 15 (71{\%}) had total involution of lesions by a median age of 13.5 months (range 7-50 months). Only mild and transient adverse effects were encountered. No neurologic complications occurred. Conclusions: Interferon-α appears to be an effective and well-tolerated treatment for alarming hemangiomas in infancy.",
keywords = "Hemangioendothelioma, Hemangioma, Infant, Interferon-α, Kasabach-Merritt syndrome",
author = "Chao, {Yu Hua} and Liang, {Der Cherng} and Chen, {Shu Huey} and Wang, {Lin Yen} and Yeh, {Ting Chi} and Liu, {Hsi Che}",
year = "2009",
month = "8",
doi = "10.1111/j.1442-200X.2008.02770.x",
language = "English",
volume = "51",
pages = "469--473",
journal = "Pediatrics International",
issn = "1328-8067",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Interferon-α for alarming hemangiomas in infants

T2 - Experience of a single institution

AU - Chao, Yu Hua

AU - Liang, Der Cherng

AU - Chen, Shu Huey

AU - Wang, Lin Yen

AU - Yeh, Ting Chi

AU - Liu, Hsi Che

PY - 2009/8

Y1 - 2009/8

N2 - Background: Hemangioma is the most common tumor in infancy. 'Alarming hemangiomas' refer to the lesions that potentially impair vital structures or cause life-endangering complications, and which warrant vigorous treatment. Interferon-α has been used for alarming hemangiomas at Mackay Memorial Hospital, Taipei, Taiwan, since 1994. Methods: The records of 21 consecutive infants treated between January 1994 and December 2005 were retrospectively reviewed. The initial dose of interferon-α was 50 000 IU/kg per day, which was increased to 100 000 IU/kg per day in the second week of therapy if tolerated. It was tapered depending on response, with total treatment lasting no longer than 12 months. Treatment response was evaluated depending on the size of the lesion and resolution of complications. Results: The duration of therapy ranged from 6 to 12 months. Six patients (29%) had a reduction in mass of ≥25% after 1 month of therapy. Twenty patients (95%) had achieved a decrease in size of 50% by 12 months, and 15 (71%) had total involution of lesions by a median age of 13.5 months (range 7-50 months). Only mild and transient adverse effects were encountered. No neurologic complications occurred. Conclusions: Interferon-α appears to be an effective and well-tolerated treatment for alarming hemangiomas in infancy.

AB - Background: Hemangioma is the most common tumor in infancy. 'Alarming hemangiomas' refer to the lesions that potentially impair vital structures or cause life-endangering complications, and which warrant vigorous treatment. Interferon-α has been used for alarming hemangiomas at Mackay Memorial Hospital, Taipei, Taiwan, since 1994. Methods: The records of 21 consecutive infants treated between January 1994 and December 2005 were retrospectively reviewed. The initial dose of interferon-α was 50 000 IU/kg per day, which was increased to 100 000 IU/kg per day in the second week of therapy if tolerated. It was tapered depending on response, with total treatment lasting no longer than 12 months. Treatment response was evaluated depending on the size of the lesion and resolution of complications. Results: The duration of therapy ranged from 6 to 12 months. Six patients (29%) had a reduction in mass of ≥25% after 1 month of therapy. Twenty patients (95%) had achieved a decrease in size of 50% by 12 months, and 15 (71%) had total involution of lesions by a median age of 13.5 months (range 7-50 months). Only mild and transient adverse effects were encountered. No neurologic complications occurred. Conclusions: Interferon-α appears to be an effective and well-tolerated treatment for alarming hemangiomas in infancy.

KW - Hemangioendothelioma

KW - Hemangioma

KW - Infant

KW - Interferon-α

KW - Kasabach-Merritt syndrome

UR - http://www.scopus.com/inward/record.url?scp=68349141130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68349141130&partnerID=8YFLogxK

U2 - 10.1111/j.1442-200X.2008.02770.x

DO - 10.1111/j.1442-200X.2008.02770.x

M3 - Article

C2 - 19400814

AN - SCOPUS:68349141130

VL - 51

SP - 469

EP - 473

JO - Pediatrics International

JF - Pediatrics International

SN - 1328-8067

IS - 4

ER -